Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

the risk that revenue may decrease due to lack of demand for products sold or under royalty or due to an increase in the cost of such products, or both; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... This report deals with therapeutic drug monitoring, ... patient care by monitoring drug levels in ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... Expo, June 3-5 in Des Moines, Iowa. , ... Wall Street Journal article because of its industry-leading ...
(Date:5/28/2015)... 28, 2015  GenVec, Inc. (Nasdaq: GNVC ) ... J. Swirsky , will present a company overview at ... EDT on Thursday, June 4, 2015. ... will be available at the following link:  http://wsw.com/webcast/jeff88/gnvc ... website.  To access, visit www.genvec.com , click on ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2
... sensing by a team of Rensselaer Polytechnic Institute researchers ... agents and illegal drugs from a distance of 20 ... wave technology, has great potential for homeland security and ... packaging materials and can identify immediately the unique THz ...
... pressing concerns of the day, fear of plague probably isn,t ... whose responsibility it is to combat bioterrorism, plague is among ... like medical researcher Steve Smiley, whose lab at the Trudeau ... the public against weaponized forms of plague. The Institute, which ...
... 15 Precision Therapeutics announced today that its ... recognized as CEO of the Year by the ... http://photos.prnewswire.com/prnh/20101015/NE83126 ) (Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 ... recognizes the accomplishments of 50 of southwestern Pennsylvania,s ...
Cached Biology Technology:A revolutionary breakthrough in terahertz remote sensing 2Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... that died 44,000 years ago in Antarctica have provided ... traditional genetic aging measurements, and suggest those approaches have ... 200 to 600 percent. In other words, a ... 100,000 years old may actually be 200,000 to 600,000 ...
... -- Agricultural soils accumulate trace metals, particularly copper ... wastes (sewage biosolids and manures) and fungicides that are ... for tolerable concentrations of these potentially plant-toxic elements in ... effects of the metals are substantially independent and not ...
... and LAS VEGAS, Nov. 9 CBS Vision, the ... Media Group company, today announced a new research partnership that will ... housed in the MGM Grand Hotel in Las Vegas. , ... one of the county,s leading agencies, will be called Communications ...
Cached Biology News:Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2Additive copper-zinc interaction affects toxic response in soybean 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4
WNV Core Antibody...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: